FP6Индивидуална стипендия2007–2009

FUNCTIONCOLLCAPS · Functionalized Colloidal Capsules

6РП — Действия „Мария Кюри“

Период
2007-09-01 → 2009-08-31
Финансиране от ЕС
169 365 €
Участници
1
Схема
EIF

Линиите свързват координатора с партньорите.

Накратко на български

Биосъвместими покрития за микрокапсули, които могат да транспортират лекарства в тялото, се разработват чрез използване на производни на декстрана. Това помага за по-доброто контролиране на освобождаването на лекарствата и предпазва капсулите от разпадане при различни нива на киселинност.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Final Activity Report Summary - FUNCTIONCOLLCAPS (Functionalised colloidal capsules)

The main aim of the project was creation of multifunctional biocompatible coating for hollow polyelectrolyte microcapsules which were proposed for encapsulation of drugs, drug delivery and controlled release. For the satisfactory performance of the hollow polyelectrolyte microcapsules, an adaptable coating providing good colloid stability, resistance against non-specific protein adsorption and targeted delivery is vital. The other researchers have developed graft-copolymers with poyelectrolyte backbones (e.g. poly(L-lysine), PLL) which can be electrostatically adsorbed onto such capsules and polyethyleneglycol (PEG) side chains providing a low zeta-potential, colloid stability and low adsorption of molecules from blood serum. However, these graft-copolymers have lack of reactive groups which may be needed for anchoring sensor molecules for targeting purposes and do not preserve integrity of the capsules made of weak polyelectrolytes (which are most of biodegradable polymers) at extreme pH values because the electrostatic charging of the capsule's polyelectrolyte constituents leads to unlimited swelling and dissolution. Limited swelling of the microcapsules at extreme pH is a much desired property because it allows loading them with drugs via diffusion through the pores at the post-preparation stage. Control over the swelling degree can be achieved via introduction of additional linkages between the polyelectrolyte chains within the capsules' walls. We have proposed dextran polyaldehyde (DPA) as such a coating which is a derivative of dextran (a natural polysaccharide) and may substitute the graft-copolymers for the reasons that dextran is biocompatible, biodegradable, has many reactive alcohol groups unlike PEG (which has only two end-groups), and chemistry of dextran and its derivatives has been well studied. We demonstrated that the DPA coatings provide a good stability of the capsules against aggregation upon storage in solutions of ions having multiple charges (calcium and phosphate ions) and preserve the integrity of the capsules at both high and low pH (0.1 M NaOH and 0.1 M HCl). On the contrary, the unmodified polyelectrolyte capsules are quickly dissolved in 0.1 M NaOH. The limiting swelling degree of the DPA-coated capsules was determined by the density of the aldehyde groups along the polysaccharide chain. The swelling in 0.1M NaOH was reversible: the capsules restored their initial size at neutral pH.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The project Functionalised Colloidal Capsules (FCC) has two goals:1) development of a universal methodology for modification of colloidal substrates (polyelectrolyte capsules) with two (several) (bio-) macromolecular functionalities providing control of their ratio and uniform distribution;2) development of a new approach for manufacturing asymmetrically (north-south) functionalised colloidal particles (polyelectrolyte capsules).The methodology developed within the 1st goal will result in manufacturing prototypes of biocompatible colloidal drug carriers with increased circulation period and better targeting efficiency for future pharmaceutical applications. One of the functionalities on the surface of a drug carrier will be responsible for hindering non-specific interactions with proteins and cells of the immune system, while the other one will provide recognition of a targeted tissue.The problem of proper control on the ratio of the two types of the (bio-) macromolecular functionalities will be solved via their preliminary coupling to a common anchoring unit (backbone) resulting in the architecture of (mixed) graft-copolymers. The approach for manufacturing asymmetrically (north-south) functionalised colloidal particles (polyelectrolyte capsules) comprises preliminary protection of one semi-sphere of the particles by reversible adsorption to an oppositely charged polyelectrolyte brush.The open surface of the partially protected colloidal particles will be modified by adsorption of graft-copolymers synthesized within the 1st goal. The non-modified area on the particles will be modified (if necessary) with another kind of graft-copolymer or linear polyelectrolyte after release of the particles back to the solution.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз